Gilead buys YM for $510m

By Andrew Turley2012-12-20T00:00:00+00:00

No comments

Deal gives Gilead access to Janus kinase inhibitor CYT387 for the treatment of myelofibrosis

US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million (£310 million).

The lead drug candidate at YM is CYT387, a selective inhibitor of the Janus kinase (JAK) enzymes, which are thought to be involved in several of disorders, including myeloproliferative diseases, inflammatory disorders and certain types of cancer.

Gilead is planning a Phase III trial of CYT387 against myelofibrosis in the second half of 2013.

YM gained CYT387 when it bought Australian biotech Cytopia in 2009.

References

Topics

No comments

Business
From philanthropy to sustainability
2019-11-20T14:27:00Z
Corporate Social Responsibility in the pharmaceutical and chemical industries is changing
Opinion
Picking the right problems
2019-11-19T14:27:00Z
Why working on something that’s just ‘interesting’ is not enough
Business
Carbon Cycle’s gypsum purification process cleans up radioactive fertiliser waste
2019-11-18T09:41:00Z
The patented process could prevent environmental damage and provide a new source of gypsum and rare-earth metals